Are sAA1 genetic polymorphisms associated with plasma glucose concentration in non-diabetic subjects?
The genetic polymorphisms of SAA1 were associated with plasma glucose levels in non-diabetic subjects.
These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast-mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.